The US Food and Drug Administration (FDA) is imposing new restrictions and warnings on JAK inhibitors in the treatment of rheumatic inflammatory disorders after a tofacitinib safety trial showed an increased risk of major adverse cardiovascular events, malignancy, thrombosis, and mortality. The measures will apply to tofacitinib, baricitinib, and upadacitinib, based on results from a ...
New safety warnings for JAK inhibitors
By Michael Woodhead
7 Sep 2021